查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2096648

細胞免疫療法市場－2026-2032年全球市場預測

Cellular Immunotherapy Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，細胞免疫療法市場將成長至 150.5 億美元，複合年成長率為 8.13%。

主要市場統計數據
基準年 2025 87億美元
預計年份：2026年 93.9億美元
預測年份 2032 150.5億美元
複合年成長率 (%) 8.13%

細胞免疫療法利用活的免疫細胞辨識、標靶並清除病變細胞，正在革新現代腫瘤學和免疫介導疾病的治療。此領域涵蓋嵌合體抗原受體T細胞療法、腫瘤浸潤淋巴細胞療法、T細胞受體療法、自然殺手細胞療法、樹突細胞疫苗以及新型同種異體細胞療法平台。其臨床意義體現在多種骨髓惡性腫瘤的法規核准以及在固體癌、自體免疫疾病、感染疾病和移植相關併發症等領域不斷擴展的臨床研究。該領域的關鍵優先事項包括提高持續緩解率、控制細胞激素釋放症候群和免疫效應細胞相關神經毒性症候群、簡化生產過程、擴大患者覆蓋範圍以及為個性化和現成療法建立可擴展的品質系統。隨著醫療保健系統擁抱精準醫療，細胞免疫療法正成為先進醫療產品的戰略支柱，其發展離不開基於生物標記的患者篩選、專業的治療中心、完善的低溫運輸物流以及日益自動化的生產流程的支持。

細胞免疫治療領域的變革性變化

科學進步、監管洞察和生產創新正在推動細胞免疫治療領域的結構性變革。儘管自體療法已在某些血液系統惡性腫瘤中展現出顯著的臨床療效，但為了滿足快速、穩定、擴充性且更廣泛的治療需求，異體療法正在不斷發展。研發方向正從單一抗原標靶化轉向多抗原標靶化、邏輯門控、強化和基因編輯細胞設計，旨在減少因抗原逃脫導致的複發並提高細胞持久性。固體癌領域的研發也在加速推進，其策略包括提高腫瘤內滲透性、克服免疫抑制微環境以及將細胞療法與查核點抑制劑、細胞激素工程、放射線治療或標靶治療相結合。在營運層面，封閉式系統處理、數位化批次記錄、分散式生產模式和標準化療效評估對於確保治療的可重複性和符合監管要求至關重要。此外，尤其是在治療途徑擴展到高度專業化的腫瘤中心之外的情況下，保險公司和醫療保健提供者正在推動該領域朝著循證價值證明、長期安全監測以及了解真實世界臨床環境中的結果的方向發展。

人工智慧對細胞免疫療法的累積影響

人工智慧 (AI) 正成為細胞免疫療法整個價值鏈（從藥物發現到臨床應用）的強大驅動力。在標靶辨識方面，AI 驅動的基因組、轉錄組、蛋白質組和單細胞資料集分析有助於篩選腫瘤相關和腫瘤特異性抗原，並有助於評估標靶和非標靶安全性風險。在治療方案設計方面，機器學習可輔助受體最佳化、指南基因編輯策略，並幫助識別與持久性、耗竭抗藥性和細胞毒性相關的細胞表現型。 AI 還有助於改進生產流程，實現預測性過程控制、異常檢測、放行檢測最佳化以及批間差異的早期識別。在臨床開發方面，先進的分析技術支援患者分層、毒性風險預測、療效監測、研究中心選擇以及在科學合理且符合監管規定的限度內分析臨床實驗或外部對照。這些努力結合起來，將為細胞免疫療法創建一個數據整合的生態系統，但領導者必須應對模型檢驗、數據互通性、演算法偏差、網路安全、可解釋性以及遵守醫療保健和生命科學領域人工智慧監管規則等挑戰。

細胞免疫療法的關鍵區域見解

亞太地區正透過擴大臨床試驗活動、政府主導的生物技術投資以及提升醫院能力以容納先進的腫瘤治療，不斷增強其在細胞免疫療法領域的影響力。其中，中國、日本、韓國、印度和澳洲是主要的研發和臨床應用中心。歐洲受益於完善的先進醫療產品監管體系、跨境科學合作以及強大的臨床研究網路，但其具體實施情況因各國醫保報銷政策、醫院準備情況、醫療技術評估要求以及專業細胞處理能力而異。北美憑藉其成熟的細胞和基因療法監管流程、強大的學術醫療中心網路、廣泛的真實世界數據（RWE）基礎設施以及在CAR-T和下一代細胞療法研究中的高度參與，仍然是重要的創新中心。拉丁美洲在癌症中心能力提升、監管現代化以及對區域製造夥伴關係日益成長的興趣的推動下，正逐步取得進展，但醫保報銷限制、地域差異和專業基礎設施不平衡仍然制約著治療的普及。非洲尚處於早期階段，在腫瘤學領域的能力建設、生物檢體網路、人力資源開發、臨床研究夥伴關係以及能夠使細胞免疫療法適應當地醫療體系實際情況的交付模式等方面存在機會。在中東，精準醫療、腫瘤卓越中心、基因組學計畫和醫療旅遊基礎設施的投資正在穩步推進，尤其是在那些制定了國家醫療改革策略並正在發展重症患者監護醫院的國家。

來自北約、七國集團、金磚國家、歐盟、東協和海灣合作理事會等主要組織的見解

儘管北約成員國並非單一的醫療衛生集團，但它們涵蓋眾多高所得國家和研發密集型醫療衛生體系，在這些體系中，生物技術準備、供應鏈韌性、網路安全和先進的生物製造能力與細胞療法的基礎設施日益緊密地交織在一起。七國集團成員國透過監管科學、臨床證據的累積、保險報銷的討論、品質預期以及對先進療法進行長期安全性追蹤的實踐，持續影響全球標準。金磚國家因其大規模的患者群體、不斷擴展的生物醫學研究能力以及對國內生產的政策重視而舉足輕重，在未來自體和異體免疫療法的准入模式中發揮著核心作用。歐盟憑藉著集中化的科學評估、藥物安全監測要求、多國研究框架和協調一致的監管指導，為先進療法藥物提供了最為結構化的環境之一，儘管國家層面的准入決策和生產能力仍然是重要的差異因素。在東南亞國協，癌症治療現代化、生物製造技術以及區域臨床合作日益受到重視，為細胞免疫療法的引入奠定了基礎。然而，在保險報銷、低溫運輸物流、人力資源開發以及先進療法相關法規方面仍存在差異。海灣合作理事會（GCC）國家正透過國家基因組學舉措、對癌症治療的專項投資以及配備先進醫療基礎設施、能夠支持複雜治療的醫院系統來增強自身實力。長期成功取決於人力資源發展、本地品管體係以及永續的病患轉診途徑。

主要國家細胞免疫療法的發展趨勢

中國是細胞免疫療法研究領域最活躍的國家之一，尤其是在CAR-T細胞療法和新型免疫細胞平台領域，這得益於大規模的臨床試驗活動、國內創新以及對先進生物醫學的政策重視。美國憑藉著廣泛的主導先例、專業的治療中心、學術研究、真實世界數據（RWE）系統以及已通過核准療法的報銷機制，在細胞免疫療法的臨床應用方面處於領先地位。日本擁有成熟的再生醫學和細胞療法法規環境、完善的臨床研究能力以及評估先進療法的經驗。印度正透過推進國產CAR-T細胞療法、拓展腫瘤學領域的能力以及旨在提高國內可及性的成本控制型生產舉措取得進展。德國和法國結合了強大的生物醫學研究、以醫院為基礎的創新、血液學專業知識以及針對先進療法的系統性保險報銷評估，而英國繼續積極監管先進療法、開展臨床試驗、協調全國範圍內的細胞療法並追蹤長期療效。澳洲支持先進的臨床研究、早期臨床試驗、轉化醫學網路和區域間合作，而韓國則憑藉強大的生物製造能力、數位化醫療體係以及對創新生物製藥開發的政策支持而取得進展。義大利和西班牙因其在血液學領域的專業知識、學術臨床網路以及在提供先進療法方面積累的豐富經驗而引人注目。加拿大透過健全的公共衛生體系、細胞療法網路和轉化醫學研究能力做出貢獻，而俄羅斯則保持著其在免疫學和腫瘤學研究方面的科研實力，儘管國際合作和醫療資源獲取受到地緣政治和監管環境的影響。巴西和墨西哥正透過發展腫瘤學基礎設施、參與區域臨床研究以及對本地先進療法能力的重視而取得進展，但公共和私人醫療保健體系的差異以及保險報銷限制影響了醫療資源的獲取。

為細胞免疫療法領域的領導者提供的實用建議

產業領導者應優先考慮具有明確臨床差異、可衡量的持久性、可接受的安全性以及可操作的生產可行性的療法，而非僅僅追求技術新穎性。各機構應投資於可擴展的封閉式生產系統、統一的品管、可靠的療效評估、檢驗的出庫檢測以及數位化身分和監管鏈系統，以降低變異性並增強監管機構的信任。臨床策略應整合基於生物標記的患者選擇、標準化的毒性管理、長期追蹤以及從研發早期階段就開始收集真實世界數據（REW）。研發人員還應加強與醫院、血站、物流供應商、認證實驗室和保險公司的夥伴關係，以確保治療路徑在營運上可行且在財務上永續。在全球推廣中，領導者必須根據當地基礎設施調整准入模式，制定本地培訓計劃，儘早與監管機構進行對話，並使證據材料符合各司法管轄區的具體要求。在實施人工智慧時，必須透過檢驗的資料集、人工監督、網路安全措施、透明的文件和持續的效能監控來管理它，以確保數位工具不會引入不可控的風險，並提高安全性、品質和決策能力。

調查方法

本執行摘要採用結構化的二級研究途徑編寫，重點關注與細胞免疫療法相關的、檢驗且有數據支持的資訊來源。此調查方法優先考慮同行評審的醫學文獻、監管指南和核准文件、臨床試驗註冊資訊、藥物安全監測要求、衛生技術評估材料、公共衛生出版刊物以及腫瘤學、血液學、免疫學和先進醫學領域的科學共識。證據評估標準包括臨床相關性、時效性、調查方法嚴謹性、監管可靠性以及跨地區和跨療法類型的適用性。採用定性綜合分析方法，識別技術趨勢、區域部署模式、營運限制、人工智慧應用和策略意義，而不考慮市場規模、市場佔有率或預測。研究結果旨在支持經營團隊決策，重點關注已證實有效的治療進展、生產和監管現狀、准入考慮以及為細胞免疫療法領域相關人員提供的可操作建議。

結論

細胞免疫療法正從一項突破性的治療類別轉型為一個更廣泛的治療平台，該平台由精準生物學、基因改造免疫細胞、先進的製造技術和真實世界數據共同塑造。該領域的下一階段將以諸多能力為標誌，例如提高安全性、擴大療效範圍（超越特定血液腫瘤）、簡化生產流程、降低准入門檻以及在常規臨床實踐中證實患者能夠持續獲益。人工智慧、自動化和生物標記科學雖然可以加速這一進程，但它們的價值取決於嚴格的檢驗、監管合規和符合倫理的數據管治。基礎設施、保險報銷、人力資源開發以及區域和國家政策差異將繼續影響該療法的應用。那些將卓越的科學技術與嚴謹的運作、循證實踐和公平的准入計劃相結合的機構，將最有能力推動細胞免疫療法從一項專業創新發展成為下一代醫療保健的組成部分。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 細胞免疫療法市場：按類型分類

  • CAR-T細胞
    • CD19
    • BCMA
    • CD22
  • TCR-T細胞
    • gp100
    • NY-ESO-1
    • MAGE-A4
  • TIL療法
    • 增生的腫瘤浸潤淋巴細胞
    • 排序 TIL
  • NK細胞療法
    • NK細胞
    • CAR-NK細胞

第8章：細胞免疫療法市場：依技術類型分類

  • 細胞激素和免疫調節劑
  • 單株抗體

第9章：細胞免疫療法市場：依適應症分類

  • B細胞惡性腫瘤
  • 肝癌
  • 攝護腺癌
  • 腎臟細胞癌

第10章：細胞免疫療法市場：依醫療機構類型分類

  • 學術機構
  • 生物技術和製藥公司
  • 承包組織
  • 醫院
  • 研究機構

第11章 細胞免疫療法市場：按地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第12章 細胞免疫療法市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第13章 細胞免疫療法市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第14章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Adaptimmune Therapeutics PLC
  • Adicet Bio, Inc.
  • Apac Biotech Private Limited
  • AstraZeneca PLC
  • Atara Biotherapeutics, Inc.
  • Bellicum Phamaceuticals, Inc.
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • Celyad Oncology SA
  • Corning Incorporated
  • Dendreon Pharmaceuticals LLC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Glycostem Therapeutics BV
  • Immatics NV
  • Inovio Pharmaceuticals, Inc.
  • Iovance Biotherapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • JW Therapeutics（Shanghai）Co., Ltd.
  • Lonza Group Ltd.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
Product Code: MRR-7C50F2739738

The Cellular Immunotherapy Market is projected to grow by USD 15.05 billion at a CAGR of 8.13% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.70 billion
Estimated Year [2026] USD 9.39 billion
Forecast Year [2032] USD 15.05 billion
CAGR (%) 8.13%

Cellular immunotherapy is reshaping modern oncology and immune-mediated disease management by using living immune cells to recognize, target, and eliminate diseased cells. The field spans chimeric antigen receptor T-cell therapy, tumor-infiltrating lymphocyte therapy, T-cell receptor therapy, natural killer cell therapy, dendritic cell vaccines, and emerging allogeneic cell therapy platforms. Its clinical relevance is supported by regulatory approvals for multiple hematologic malignancies and expanding clinical research across solid tumors, autoimmune disorders, infectious diseases, and transplant-related complications. Key industry priorities include improving durable response rates, managing cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, reducing manufacturing complexity, broadening patient access, and establishing scalable quality systems for personalized and off-the-shelf therapies. As healthcare systems adopt precision medicine, cellular immunotherapy is becoming a strategic pillar of advanced therapy medicinal products, supported by biomarker-driven patient selection, specialized treatment centers, robust cold-chain logistics, and increasingly automated manufacturing workflows.

Transformative Shifts in the Cellular Immunotherapy Landscape

The cellular immunotherapy landscape is undergoing structural transformation as scientific advances, regulatory experience, and manufacturing innovation converge. Autologous therapies have demonstrated meaningful clinical benefit in specific blood cancers, while allogeneic approaches are being developed to address treatment speed, consistency, scalability, and broader availability. Research is shifting from single-antigen targeting toward multi-antigen, logic-gated, armored, and gene-edited cell designs intended to reduce relapse associated with antigen escape and improve persistence. Solid tumor development is also accelerating through strategies that improve tumor trafficking, overcome immunosuppressive microenvironments, and combine cellular therapy with checkpoint inhibition, cytokine engineering, radiation, or targeted therapy. At the operational level, closed-system processing, digital batch records, decentralized manufacturing models, and standardized potency assays are becoming essential to support reproducibility and regulatory compliance. Payers and providers are also pushing the sector toward evidence-based value demonstration, long-term safety monitoring, and real-world outcomes capture, especially as treatment pathways move beyond highly specialized oncology centers.

Cumulative Impact of Artificial Intelligence on Cellular Immunotherapy

Artificial intelligence is becoming a practical accelerator across the cellular immunotherapy value chain, from discovery to clinical delivery. In target identification, AI-enabled analysis of genomic, transcriptomic, proteomic, and single-cell datasets supports the selection of tumor-associated and tumor-specific antigens and helps assess on-target, off-tumor safety risk. In therapy design, machine learning can assist receptor optimization, guide gene-editing strategies, and identify cell phenotypes associated with persistence, exhaustion resistance, and cytotoxic function. AI is also improving manufacturing by enabling predictive process control, anomaly detection, release-test optimization, and earlier identification of batch variability. In clinical development, advanced analytics support patient stratification, toxicity risk prediction, response monitoring, trial-site selection, and synthetic or external control analysis where scientifically appropriate and regulatorily acceptable. The cumulative impact is a more data-integrated cellular immunotherapy ecosystem, but leaders must address model validation, data interoperability, algorithmic bias, cybersecurity, explainability, and compliance with evolving rules governing AI in healthcare and life sciences.

Key Regional Insights for Cellular Immunotherapy

Asia-Pacific is gaining prominence in cellular immunotherapy through expanding clinical trial activity, government-backed biotechnology investment, and growing hospital capacity for advanced oncology care, with China, Japan, South Korea, India, and Australia serving as major centers for development and clinical adoption. Europe benefits from established advanced therapy medicinal product regulation, cross-border scientific collaboration, and strong clinical research networks, while implementation varies by national reimbursement policy, hospital readiness, health technology assessment requirements, and capacity for specialized cell processing. North America remains a critical innovation hub due to mature regulatory pathways for cell and gene therapies, a deep academic medical center network, extensive real-world evidence infrastructure, and high participation in CAR-T and next-generation cell therapy research. Latin America is advancing gradually, led by improving cancer center capabilities, regulatory modernization, and rising interest in regional manufacturing partnerships, though access remains shaped by reimbursement constraints, geographic disparities, and uneven specialist infrastructure. Africa is at an earlier stage, with opportunities tied to oncology capacity building, biospecimen networks, workforce training, clinical research partnerships, and delivery models that can adapt cellular immunotherapy to local health system realities. The Middle East is investing in precision medicine, oncology centers of excellence, genomics programs, and medical tourism infrastructure, particularly in countries with national health transformation strategies and high-acuity hospital development.

Key Group Insights Across NATO, G7, BRICS, EU, ASEAN, and GCC

NATO-aligned countries, while not a healthcare bloc, include many high-income and research-intensive systems where biopreparedness, supply-chain resilience, cybersecurity, and advanced biomanufacturing capabilities increasingly intersect with cellular therapy infrastructure. G7 members continue to influence global standards through regulatory science, clinical evidence generation, reimbursement debate, quality expectations, and long-term safety follow-up practices for advanced therapies. BRICS economies are relevant because they combine large patient populations, expanding biomedical research capacity, and policy interest in domestic production, making them central to future access models for autologous and allogeneic immunotherapies. The European Union provides one of the most structured environments for advanced therapy medicinal products, supported by centralized scientific evaluation, pharmacovigilance expectations, multinational research frameworks, and coordinated regulatory guidance, although country-level access decisions and manufacturing capacity remain important differentiators. ASEAN countries are increasingly prioritizing cancer care modernization, biomanufacturing skills, and regional clinical collaboration, creating a foundation for cellular immunotherapy adoption while still facing variability in reimbursement, cold-chain logistics, workforce readiness, and advanced therapy regulation. The GCC is strengthening its position through national genomics initiatives, specialized oncology investments, and high-acuity hospital systems capable of supporting complex therapies, with long-term success dependent on workforce development, local quality infrastructure, and sustainable patient referral pathways.

Key Country Insights for Cellular Immunotherapy

China has become one of the most active countries in cellular immunotherapy research, particularly in CAR-T and novel immune cell platforms, supported by large clinical trial activity, domestic innovation, and policy attention to advanced biomedicine. The United States leads in cellular immunotherapy clinical translation through extensive regulatory precedent, specialized treatment centers, academic research, real-world evidence systems, and reimbursement mechanisms for approved therapies. Japan has a mature regenerative medicine and cell therapy regulatory environment, with established clinical research capacity and experience in advanced therapy evaluation. India is progressing through indigenous CAR-T development, expanding oncology capacity, and cost-conscious manufacturing initiatives aimed at improving domestic access. Germany and France combine strong biomedical research, hospital-based innovation, hematology expertise, and structured reimbursement evaluation for advanced therapies, while the United Kingdom remains active in advanced therapy regulation, clinical trial delivery, national cell therapy coordination, and long-term outcomes tracking. Australia supports advanced clinical research, early-phase trials, translational networks, and regional collaboration, while South Korea is advancing through strong biomanufacturing, digital health capacity, and policy support for innovative biopharmaceutical development. Italy and Spain are notable for hematology expertise, academic clinical networks, and growing experience with advanced therapy delivery. Canada contributes through strong public health systems, cell therapy networks, and translational research capacity, while Russia maintains scientific capabilities in immunology and oncology research, though international collaboration and access dynamics are affected by geopolitical and regulatory conditions. Brazil and Mexico are building momentum through oncology infrastructure development, regional clinical research participation, and interest in local advanced therapy capabilities, with access influenced by public-private care differences and reimbursement constraints.

Actionable Recommendations for Cellular Immunotherapy Leaders

Industry leaders should prioritize therapies with clearly defined clinical differentiation, measurable durability, acceptable safety profiles, and practical manufacturability rather than pursuing technological novelty alone. Organizations should invest in scalable closed-system manufacturing, harmonized quality controls, robust potency assays, validated release testing, and digital chain-of-identity and chain-of-custody systems to reduce variability and support regulatory confidence. Clinical strategies should integrate biomarker-led patient selection, standardized toxicity management, long-term follow-up, and real-world evidence generation from the earliest stages of development. Developers should also strengthen partnerships with hospitals, blood centers, logistics providers, accredited laboratories, and payers to ensure that treatment pathways are operationally feasible and financially sustainable. For global expansion, leaders should adapt access models to regional infrastructure, build local training programs, and pursue regulatory engagement early to align evidence packages with jurisdiction-specific expectations. AI adoption should be governed by validated datasets, human oversight, cybersecurity controls, transparent documentation, and continuous performance monitoring to ensure that digital tools improve safety, quality, and decision-making without introducing unmanageable risk.

Research Methodology

This executive summary is developed using a structured secondary research approach focused on verified, data-backed sources relevant to cellular immunotherapy. The methodology prioritizes peer-reviewed medical literature, regulatory guidance and approval documentation, clinical trial registries, pharmacovigilance requirements, health technology assessment materials, public health agency publications, and scientific consensus from oncology, hematology, immunology, and advanced therapy domains. Evidence was assessed for clinical relevance, recency, methodological rigor, regulatory credibility, and applicability across regions and therapy types. Qualitative synthesis was used to identify technology trends, regional adoption patterns, operational constraints, AI applications, and strategic implications without relying on market sizing, market share, or forecasting. Findings were organized to support executive decision-making, emphasizing validated therapeutic progress, manufacturing and regulatory realities, access considerations, and practical recommendations for stakeholders operating in cellular immunotherapy.

Conclusion

Cellular immunotherapy is moving from a breakthrough treatment category toward a broader therapeutic platform shaped by precision biology, engineered immune cells, advanced manufacturing, and real-world evidence. The sector's next phase will be defined by the ability to improve safety, expand efficacy beyond select hematologic cancers, simplify production, reduce access barriers, and demonstrate durable patient benefit in routine care. Artificial intelligence, automation, and biomarker science can accelerate progress, but their value depends on rigorous validation, regulatory alignment, and ethical data governance. Regional and country-level differences in infrastructure, reimbursement, workforce readiness, and policy will continue to influence adoption. Organizations that combine scientific excellence with operational discipline, evidence generation, and equitable access planning will be best positioned to advance cellular immunotherapy from specialized innovation to an integrated component of next-generation healthcare.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cellular Immunotherapy Market, by Type

  • 7.1. Introduction
  • 7.2. CAR-T Cells
    • 7.2.1. CD19
    • 7.2.2. BCMA
    • 7.2.3. CD22
  • 7.3. TCR-T Cells
    • 7.3.1. gp100
    • 7.3.2. NY-ESO-1
    • 7.3.3. MAGE-A4
  • 7.4. TIL Therapy
    • 7.4.1. Expanded TILs
    • 7.4.2. Selected TILs
  • 7.5. NK Cell Therapy
    • 7.5.1. NK Cells
    • 7.5.2. CAR-NK Cells

8. Cellular Immunotherapy Market, by Technology Type

  • 8.1. Introduction
  • 8.2. Cytokines & Immunomodulators
  • 8.3. Monoclonal Antibodies

9. Cellular Immunotherapy Market, by Indication

  • 9.1. Introduction
  • 9.2. B-Cell Malignancies
  • 9.3. Liver Cancer
  • 9.4. Prostate Cancer
  • 9.5. Renal Cell Carcinoma

10. Cellular Immunotherapy Market, by Institution Category

  • 10.1. Introduction
  • 10.2. Academic Institutes
  • 10.3. Biotech & Pharmaceutical Companies
  • 10.4. Contract Organizations
  • 10.5. Hospitals
  • 10.6. Research Institutes

11. Cellular Immunotherapy Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. Europe
  • 11.3. North America
  • 11.4. Latin America
  • 11.5. Africa
  • 11.6. Middle East

12. Cellular Immunotherapy Market, by Group

  • 12.1. NATO
  • 12.2. G7
  • 12.3. BRICS
  • 12.4. European Union
  • 12.5. ASEAN
  • 12.6. GCC

13. Cellular Immunotherapy Market, by Country

  • 13.1. China
  • 13.2. United States
  • 13.3. Japan
  • 13.4. India
  • 13.5. Germany
  • 13.6. United Kingdom
  • 13.7. Australia
  • 13.8. France
  • 13.9. South Korea
  • 13.10. Italy
  • 13.11. Canada
  • 13.12. Russia
  • 13.13. Brazil
  • 13.14. Mexico
  • 13.15. Spain

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. FPNV Positioning Matrix, 2025
  • 14.3. Market Concentration Analysis, 2025
    • 14.3.1. Concentration Ratio (CR)
    • 14.3.2. Herfindahl Hirschman Index (HHI)
  • 14.4. Recent Developments & Impact Analysis, 2025
  • 14.5. Product Portfolio Analysis, 2025
  • 14.6. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Adaptimmune Therapeutics PLC
  • 15.2. Adicet Bio, Inc.
  • 15.3. Apac Biotech Private Limited
  • 15.4. AstraZeneca PLC
  • 15.5. Atara Biotherapeutics, Inc.
  • 15.6. Bellicum Phamaceuticals, Inc.
  • 15.7. Bio-Rad Laboratories, Inc.
  • 15.8. Bristol-Myers Squibb Company
  • 15.9. Celyad Oncology SA
  • 15.10. Corning Incorporated
  • 15.11. Dendreon Pharmaceuticals LLC
  • 15.12. Eli Lilly and Company
  • 15.13. F. Hoffmann-La Roche AG
  • 15.14. Gilead Sciences, Inc.
  • 15.15. GlaxoSmithKline PLC
  • 15.16. Glycostem Therapeutics B.V.
  • 15.17. Immatics N.V.
  • 15.18. Inovio Pharmaceuticals, Inc.
  • 15.19. Iovance Biotherapeutics, Inc.
  • 15.20. Johnson & Johnson Services, Inc.
  • 15.21. JW Therapeutics (Shanghai) Co., Ltd.
  • 15.22. Lonza Group Ltd.
  • 15.23. Merck KGaA
  • 15.24. Novartis AG
  • 15.25. Pfizer Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELLULAR IMMUNOTHERAPY MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CELLULAR IMMUNOTHERAPY MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CELLULAR IMMUNOTHERAPY MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CELLULAR IMMUNOTHERAPY MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 21. GLOBAL CELLULAR IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CAR-T CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CAR-T CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CAR-T CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CD19 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CD19 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CD19 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BCMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BCMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BCMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CD22 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CD22 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CD22 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TCR-T CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TCR-T CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TCR-T CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GP100 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GP100 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GP100 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NY-ESO-1 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NY-ESO-1 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NY-ESO-1 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MAGE-A4 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MAGE-A4 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MAGE-A4 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TIL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TIL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TIL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL EXPANDED TILS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL EXPANDED TILS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL EXPANDED TILS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SELECTED TILS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SELECTED TILS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SELECTED TILS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NK CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NK CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NK CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NK CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NK CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NK CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CAR-NK CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CAR-NK CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CAR-NK CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CYTOKINES & IMMUNOMODULATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CYTOKINES & IMMUNOMODULATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CYTOKINES & IMMUNOMODULATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL B-CELL MALIGNANCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL B-CELL MALIGNANCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL B-CELL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LIVER CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LIVER CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LIVER CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PROSTATE CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PROSTATE CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PROSTATE CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RENAL CELL CARCINOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RENAL CELL CARCINOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RENAL CELL CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ACADEMIC INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ACADEMIC INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ACADEMIC INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOTECH & PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOTECH & PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOTECH & PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CONTRACT ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CONTRACT ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CONTRACT ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TCR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TIL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TCR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TIL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TCR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TIL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TCR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TIL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TCR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TIL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TCR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TIL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 141. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TCR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 142. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TIL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 143. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 146. NATO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 147. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 150. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TCR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 151. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TIL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 152. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 155. G7 CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TCR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TIL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TCR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TIL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TCR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TIL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 183. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 186. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TCR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 187. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TIL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 191. GCC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TCR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TIL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TCR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TIL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 211. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 214. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TCR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 215. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TIL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 216. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 217. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 219. JAPAN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 220. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 223. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TCR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 224. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TIL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 225. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 226. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 228. INDIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 229. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 232. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TCR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 233. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TIL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 234. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 235. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 237. GERMANY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TCR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TIL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED KINGDOM CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 247. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 250. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TCR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 251. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TIL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 252. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 253. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 255. AUSTRALIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 256. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 259. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TCR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 260. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TIL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 261. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 262. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 264. FRANCE CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 265. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 266. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 268. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TCR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 269. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TIL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 270. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 271. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 273. SOUTH KOREA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 274. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 277. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TCR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 278. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TIL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 279. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 280. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 282. ITALY CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 283. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 286. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TCR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 287. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TIL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 288. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 289. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 291. CANADA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 292. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 293. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 295. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TCR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 296. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TIL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 297. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 298. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 300. RUSSIA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 301. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 304. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TCR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 305. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TIL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 306. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 307. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 309. BRAZIL CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 310. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 311. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 313. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TCR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 314. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TIL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 315. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 316. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 318. MEXICO CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 319. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 320. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY CAR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 322. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TCR-T CELLS, 2018-2032 (USD MILLION)
  • TABLE 323. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TIL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 324. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY NK CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 325. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 326. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 327. SPAIN CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INSTITUTION CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 328. GLOBAL CELLULAR IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 329. GLOBAL CELLULAR IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025